Monitoring neoadjuvant chemotherapy in breast cancer patients using CEST and 
31P-MRS at 7 tesla

Krikken, E; Khlebnikov, V; Zaiss, M; van der Kemp, WJM; van der Velden, TA; van Laarhoven, HWM; Klomp, DWJ; Wijnen, JP

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

ポスター

Monitoring neoadjuvant chemotherapy in breast cancer patients using CEST and 31P-MRS at 7 tesla

MPS-Authors

/persons/resource/persons214560

Zaiss, M
Max Planck Institute for Biological Cybernetics, Max Planck Society;
Department High-Field Magnetic Resonance, Max Planck Institute for Biological Cybernetics, Max Planck Society;

External Resource

Link
(全文テキスト（全般）)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Krikken, E., Khlebnikov, V., Zaiss, M., van der Kemp, W., van der Velden, T., van Laarhoven, H., Klomp, D., & Wijnen, J. (2017). Monitoring neoadjuvant chemotherapy in breast cancer patients using CEST and 31P-MRS at 7 tesla. Poster presented at 25th Annual Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine (ISMRM 2017), Honolulu, HI, USA.

引用: https://hdl.handle.net/21.11116/0000-0000-C4D9-E

要旨

Treatment monitoring is of importance for breast cancer patients receiving systemic therapy. Metabolic imaging methods such as CEST and 31P-MRS may have potential to predict treatment efficacy in an early stage of the treatment. In this study we assessed the amide proton transfer (APT) signal and the pH change in breast cancer patients before and after the first cycle of neoadjuvant chemotherapy to explore the relation between APT and pH. We observed changes in both the APT signal and the pH between the two measurements. These changes may serve as biomarkers for predicting treatment response to NAC in an early stage.